Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Samsung Biologics’ Q3/24 Results: Accumulated Revenue at Record High

Oct 23, 2024

Samsung Biologics has announced its Q3/2024 financial results, reporting that its accumulated revenue has surpassed KRW 3T for the first time and raising its annual revenue growth guidance to +15-20%.  Samsung’s consolidated revenue reached KRW 1.2T for the quarter, an increase of 15% from Q3/2023.

Samsung Biologics’ quarterly highlights include entering into its largest contract manufacturing organisation (CMO) deal to date with an unnamed US based pharmaceutical company valued at KRW 1.7T (USD $1.06b) and securing 17 out of the global top 20 big pharma companies as clients.

Its subsidiary, Samsung Bioepis, reports increased revenue and operating profit of 26% and 38%, respectively, YOY.  Its quarterly highlights include the launch of ustekinumab biosimilar SB17 in Europe (as Pyzchiva® in July 2024) and Korea (as Epyztek™, approved in April 2024), approval of eculizumab biosimilar SB12 in the US (as Epysqli in July 2024) and a positive CHMP opinion for aflibercept biosimilar SB15 in Europe (as Opuviz in September 2024).